biomodal
biomodal logo

biomodal

Using epigenetics to reduce several diagnostic tests for common cancers to a simple blood draw.

About

Founded

2012

Headquarters

Cambridge, England, United Kingdom

Industry

Biotech

Company Description

biomodal is an omics based life-sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.

Quick Links

WebsiteJobs

Funding

Total Raised

$155.2 million

Valuation

Undisclosed

Significant Investors

Sequoia Capital, Kleiner Perkins, GV, New Science Ventures

Company Traction

  • In 2023, biomodal launched a new duet multiomics solution to sequence genetics and epigenetics in one workflow simultaneously.
  • In 2023, biomodal’s CEGX team was published in Nature Biotechnology.

Leadership Team

  • Peter Fromen: CEO at biomodal. Former Chief Commerical Officer at Pacific Biosciences.
  • Joanna Holbrook: Chief Scientific Officer at biomodal. Former VP of Translational Medicine BenevolentAI.
  • Fiona Stewart: CFO at biomodal. Former CFO at Fusion Global Capital.
  • Donna McDade Walker: VP of Product Management & Global Marketing at biomodal. Former Senior Director of Marketing at Twist Bioscience.
  • Jörg Schmitt: Head of Global Manufacturing Operations at biomodal. Former Head of Manufacturing & Supply Chain at Oxford Immunotec.

Press

People also viewed